CY1107512T1 - Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους - Google Patents

Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους

Info

Publication number
CY1107512T1
CY1107512T1 CY20061101834T CY061101834T CY1107512T1 CY 1107512 T1 CY1107512 T1 CY 1107512T1 CY 20061101834 T CY20061101834 T CY 20061101834T CY 061101834 T CY061101834 T CY 061101834T CY 1107512 T1 CY1107512 T1 CY 1107512T1
Authority
CY
Cyprus
Prior art keywords
dosage
omeprazole
dosage form
sodium bicarbonate
petrol
Prior art date
Application number
CY20061101834T
Other languages
English (en)
Inventor
Jeffrey O Phillips
Original Assignee
The Curators Of The University Of Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23911053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107512(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Curators Of The University Of Missouri filed Critical The Curators Of The University Of Missouri
Publication of CY1107512T1 publication Critical patent/CY1107512T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Νέα φαρμακευτική σύνθεση που περιέχει έναν ΡΡI και ένα ρυθμιστικό παράγοντα στη θεραπεία των διαταραχών του γαστρικού οξέος.
CY20061101834T 2000-01-11 2006-12-20 Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους CY1107512T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/481,207 US6489346B1 (en) 1996-01-04 2000-01-11 Substituted benzimidazole dosage forms and method of using same
EP01904818A EP1246622B1 (en) 2000-01-11 2001-01-10 Novel substituted benzimidazole dosage forms and method of using same

Publications (1)

Publication Number Publication Date
CY1107512T1 true CY1107512T1 (el) 2013-03-13

Family

ID=23911053

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101834T CY1107512T1 (el) 2000-01-11 2006-12-20 Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους

Country Status (21)

Country Link
US (7) US6489346B1 (el)
EP (4) EP1430895A1 (el)
JP (4) JP2003519656A (el)
KR (1) KR100679767B1 (el)
AT (1) ATE340574T1 (el)
AU (2) AU782488B2 (el)
BR (1) BR0107565A (el)
CA (1) CA2396159C (el)
CY (1) CY1107512T1 (el)
DE (1) DE60123381T2 (el)
DK (1) DK1246622T3 (el)
ES (1) ES2275650T3 (el)
IL (2) IL150696A0 (el)
MX (1) MXPA02006780A (el)
NO (1) NO331542B1 (el)
NZ (1) NZ520121A (el)
PL (1) PL201906B1 (el)
PT (1) PT1246622E (el)
RU (1) RU2279276C2 (el)
WO (1) WO2001051050A1 (el)
ZA (1) ZA200205512B (el)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
JP2002501897A (ja) * 1998-01-30 2002-01-22 セプラコール， インク． Ｒ−ランソプラゾール組成物及び方法
CA2581111A1 (en) * 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
EP1429746B1 (en) 2001-09-28 2008-08-13 McNEIL-PPC, INC. Dosage forms having an inner core and outer shell
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
WO2003053221A2 (en) * 2001-12-19 2003-07-03 Eisai Co. Ltd Methods using proton pump inhibitors
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
WO2004004682A2 (en) * 2002-07-02 2004-01-15 Laboratorios S.A.L.V.A.T., S.A. Stable oily suspension of microgranules
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
US20060140985A1 (en) * 2003-01-10 2006-06-29 Zhong Zhang Lansoprazole formulations and related processes and methods
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
AU2005204242B2 (en) * 2003-02-20 2009-10-01 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
EP1607088B1 (en) * 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005011591A2 (en) * 2003-08-01 2005-02-10 Altana Pharma Ag Method for the treatment of sleep disorders
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
CA2538910A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005044223A1 (en) * 2003-11-07 2005-05-19 Takeda Pharmaceutical Company Limited Chewable tablet
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
DE102004007854A1 (de) * 2004-02-17 2005-09-01 Hexal Ag Stabile, wässrige Formulierung für Benzimidazole
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
EP1750767A4 (en) * 2004-05-25 2010-09-22 Santarus Inc PHARMACEUTICAL FORMULATIONS USEFUL IN INHIBITING ACID SECRETION AND METHODS OF MAKING AND USING SAME
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
FR2873924A1 (fr) * 2004-08-03 2006-02-10 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s) et sa preparation
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
US20080213395A1 (en) * 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
CN101107013A (zh) * 2004-11-22 2008-01-16 阿纳迪斯有限公司 生物活性组合物
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
CN103479582A (zh) * 2005-02-03 2014-01-01 武田奈科明有限公司 制备含钙组合物的快速湿聚结方法
US7312217B2 (en) * 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US20060210480A1 (en) * 2005-03-21 2006-09-21 Shaheen Hamdy Treatment of reduction of dysphagia
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006116582A2 (en) * 2005-04-26 2006-11-02 The Curators Of The University Of Missouri Pharmaceutical compositions comprising a substituted benzimidazole, buffering agent and vitamin b12
US10307581B2 (en) * 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US20100086572A1 (en) * 2005-05-13 2010-04-08 Rajneesh Taneja Rational ppi dosage forms
WO2006123207A2 (en) * 2005-05-20 2006-11-23 Vecta, Ltd. A kit for inhibiting gastric acid secretion having an adjustable amount of ph regulating agent
WO2007041630A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
KR20080081071A (ko) 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
WO2007099433A2 (en) * 2006-02-28 2007-09-07 Wockhardt Ltd Delayed release dosage form of pantoprazole or salt thereof
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
GB2444593B (en) * 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US20080145423A1 (en) * 2006-12-14 2008-06-19 Ajmal Ali Khan Chewable tablet and method of formulating
US20080166423A1 (en) * 2007-01-06 2008-07-10 Renjit Sundharadas Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
EP2262475A1 (en) * 2008-04-01 2010-12-22 Schering-Plough Healthcare Products, Inc. Chewable tablet and method of formulating
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
WO2010042203A1 (en) * 2008-10-10 2010-04-15 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of zymogen
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
IN2012DN00359A (el) * 2009-07-20 2015-05-22 Vetegen Llc
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
TWI463998B (zh) * 2009-12-31 2014-12-11 Synmosa Biopharma Corp Amoxicillin and clomycin have a high absorption rate of pharmaceutical ingredients
EP2523654A4 (en) * 2010-01-11 2014-08-06 Mohamed Shafee Muneera IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
US9675102B2 (en) * 2010-09-07 2017-06-13 R. J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
AU2012340381B2 (en) * 2011-11-15 2017-04-06 Solventum Intellectual Properties Company Medical dressings, systems, and methods with thermally- enhanced vapor transmission
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20140371174A1 (en) 2013-06-12 2014-12-18 The Procter & Gamble Company Effervescent Dosage Form
WO2013188483A1 (en) * 2012-06-12 2013-12-19 The Procter & Gamble Company Effervescent dosage form
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
US20140323419A1 (en) * 2013-04-24 2014-10-30 Tat-Kin Tsang High efficacy combination therapy for helicobacter pylori eradication and packaging for the distribution and use thereof
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA2987034C (en) * 2015-05-29 2023-03-07 Johnson & Johnson Consumer Inc. Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US11207307B2 (en) 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102419769B1 (ko) 2016-08-11 2022-07-13 아다미스 파마슈티칼스 코포레이션 약물 조성물
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
CN108686194A (zh) * 2018-08-20 2018-10-23 李时珍（广州）健康科技有限公司 一种改善小儿肠胃功能的中药泡浴组合物、其制备方法及应用
CN112839635A (zh) 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
KR102290295B1 (ko) 2019-07-26 2021-08-17 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
TW202126301A (zh) * 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
KR102573842B1 (ko) 2020-02-21 2023-09-01 주식회사 종근당 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
KR20210012881A (ko) 2020-02-28 2021-02-03 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006862A (en) * 1932-12-29 1935-07-02 American Anode Inc Manufacture of articles from aqueous rubber dispersions
US4045564A (en) 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
US4252790A (en) * 1974-10-23 1981-02-24 Interx Research Corporation Method for treating gastric ulcer-prone patients
JPS52102416A (en) 1976-02-19 1977-08-27 Okawara Mfg Granule making method of herb medicine and like
IN148930B (el) 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6043064B2 (ja) 1979-11-28 1985-09-26 ウェルファイド株式会社 新規イソオキサゾ−ル誘導体
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
JPS57212180A (en) 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
RO88351A3 (ro) 1984-04-26 1986-04-30 Intreprinderea De Medicamente"Terapia",Ro Compozitie pentru tratamentul afectiunilor gastroduodenale
SE8403179D0 (sv) 1984-06-13 1984-06-13 Haessle Ab New compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS62145083A (ja) 1985-12-18 1987-06-29 Yoshitomi Pharmaceut Ind Ltd 縮合イミダゾ−ル誘導体
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
SE8604566D0 (sv) 1986-10-27 1986-10-27 Haessle Ab Novel compunds
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5215974A (en) 1986-11-21 1993-06-01 Aktiebolaget Hassle Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases
US4965264A (en) 1987-03-25 1990-10-23 Yoshitomi Pharmaceutical Industries, Ltd. Thienocinnoline compounds and their pharmaceutical use
NZ224252A (en) 1987-04-21 1991-09-25 Erba Carlo Spa An anthracycline glycoside and its preparation
WO1989000566A1 (en) 1987-07-21 1989-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compounds and medicinal use thereof
ES2043766T3 (es) 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
WO1990000054A1 (en) 1988-06-30 1990-01-11 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
EP0394471A4 (en) 1988-09-21 1991-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Thienocycloheptapyridazine compounds and medicinal uses thereof
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IE64199B1 (en) 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
JP2694361B2 (ja) 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
DK0382489T3 (da) 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
SE8903563D0 (sv) 1989-10-26 1989-10-26 Haessle Ab A novel dissolution system
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
US5254682A (en) * 1989-12-08 1993-10-19 Merck & Co., Inc. Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2038716A1 (en) 1990-03-28 1991-09-29 Yoshio Ueda Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-containing preparation, stabilizing method thereof and drug stabilized thereby
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
ATE184602T1 (de) 1990-06-20 1999-10-15 Astra Ab Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
CA2092694C (en) 1990-09-14 2005-04-05 Kurt Klemm Use of pyridylmethylsulphinyl-1h-benzimidazole derivates in the treatment of illnesses caused by helicobacter bacteria
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
WO1992012976A1 (en) 1991-01-16 1992-08-06 Yoshitomi Pharmaceutical Industries, Ltd. Use of pyridine compound as selective drug and novel pyridine compound
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
NZ244301A (en) 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
WO1993005770A1 (en) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
JPH05117268A (ja) 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
US5339700A (en) 1991-12-16 1994-08-23 Isco, Inc. Sample collector
TW224049B (el) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW276996B (el) 1992-04-24 1996-06-01 Astra Ab
US5504082A (en) 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
SK279554B6 (sk) 1992-07-28 1998-12-02 Astra Aktiebolag Jeho analógy
JPH0656665A (ja) 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
WO1995007913A1 (fr) 1993-09-17 1995-03-23 Meiji Milk Products Co., Ltd. Agent antibacterien et antifongique
WO1995008332A1 (en) 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
ES2179079T3 (es) 1993-10-12 2003-01-16 Mitsubishi Pharma Corp Comprimidos que contienen granulos entericos.
US5762962A (en) * 1994-10-05 1998-06-09 Warner-Lambert Company Antacid pharmaceutical composition
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
IS4232A (is) 1993-12-06 1995-06-07 Astra Aktiebolag Súbstitúerað bensimidasól, aðferðir við framleiðslu þess og lyfjafræðileg notkun
WO1995018612A1 (en) 1994-01-05 1995-07-13 Aktiebolaget Astra A method for treatment of psoriasis, by omeprazole or related compounds
KR0179401B1 (ko) 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
DE670160T1 (de) 1994-03-01 1996-03-14 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
ATE182073T1 (de) * 1994-03-01 1999-07-15 Gerhard Gergely Ein brausesystem und einen arzneiwirkstoff enthaltendes granuläres produkt bzw. tablette sowie verfahren zu deren herstellung
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
WO1995032957A1 (en) 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
BR9506018A (pt) 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
MX9700152A (es) 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
SE9404192D0 (sv) 1994-12-02 1994-12-02 Astra Ab New process
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
AU5780696A (en) 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9503102D0 (sv) 1995-09-08 1995-09-08 Astra Ab Aseptic transfer
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
CA2235304A1 (en) 1995-10-17 1997-04-24 Thomas Mcinally Pharmaceutically active quinazoline compounds
SE521100C2 (sv) 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19628643A1 (de) 1996-07-16 1998-01-22 Merck Patent Gmbh Werkstoffe für die Herstellung von Transportbehältern
US5766622A (en) 1996-08-14 1998-06-16 The Procter & Gamble Company Inhibiting undesirable taste in oral compositions
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
US5885594A (en) 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
TW550090B (en) 1997-05-09 2003-09-01 Sage Pharmaceuticals Inc Stable oral pharmaceutical dosage forms for acid-unstable drug
US5939091A (en) 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
US20010053387A1 (en) 1997-05-23 2001-12-20 Hamied Yusuf Khwaja Benzimidazole pharmaceutical composition and process of prepatation
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process
WO1999027917A1 (de) 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
ATE303809T1 (de) 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
IT1299198B1 (it) 1998-03-05 2000-02-29 Nicox Sa Sali nitrati di farmaci antiulcera
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB2338896B (en) 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US6503431B1 (en) * 1998-07-08 2003-01-07 Mitsui Chemicals Inc Process for manufacturing an extruded article and an extruded article
US6166213A (en) 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
AU772726B2 (en) 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
US6713089B1 (en) 1998-09-10 2004-03-30 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
WO2000026185A2 (en) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Omeprazole solution and method of using same
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ATE271556T1 (de) 1998-11-18 2004-08-15 Astrazeneca Ab Verbesserter chemischer prozess und eine pharmazeutische zubereitung
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
KR100299562B1 (ko) * 1998-12-29 2001-11-22 우재영 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립
JP2000212180A (ja) 1999-01-21 2000-08-02 Welfide Corp キノリン化合物
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
EP1156806B1 (en) 1999-02-23 2004-04-07 Merck & Co., Inc. Pharmaceutical composition containing proton pump inhibitors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9911017D0 (en) 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
MXPA02000107A (es) 1999-06-22 2002-07-02 Neurosearch As Derivados de benzimidazol novedososy composiciones farmaceuticas que comprenden estos compuestos.
PL352383A1 (en) 1999-06-28 2003-08-25 Sankyo Co Semi-finished products for synthesis of derivatives of benzimidazole and method of obtaining same
EP1191025B1 (en) * 1999-06-30 2005-06-22 Takeda Pharmaceutical Company Limited Crystals of lansoprazole
JP2003504338A (ja) 1999-07-12 2003-02-04 スミスクライン・ビーチャム・コーポレイション 胸やけの処置法
US6268385B1 (en) * 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
AU6937700A (en) 1999-08-26 2001-03-19 Applied Analytical Industries, Inc. Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1221947B1 (en) 1999-10-01 2004-12-08 Natco Pharma Limited Soft gel capsule resistant to gastric juices
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
EP1313736B1 (en) * 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
CA2386716C (en) 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US20020064555A1 (en) 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US6608091B2 (en) * 2001-04-20 2003-08-19 Linda B. Whittall Process for purifying 6-methoxy omeprazole
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
AU2002365936A1 (en) 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
JP2005533755A (ja) * 2002-03-27 2005-11-10 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール多形及びその調製方法
AR045062A1 (es) 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas

Also Published As

Publication number Publication date
NO331542B1 (no) 2012-01-23
BR0107565A (pt) 2003-02-11
PT1246622E (pt) 2007-01-31
EP1927354A1 (en) 2008-06-04
AU2005229686B2 (en) 2009-08-20
US6780882B2 (en) 2004-08-24
RU2279276C2 (ru) 2006-07-10
CA2396159A1 (en) 2001-07-19
ES2275650T3 (es) 2007-06-16
KR20020089322A (ko) 2002-11-29
ATE340574T1 (de) 2006-10-15
KR100679767B1 (ko) 2007-02-07
DE60123381D1 (de) 2006-11-09
AU782488B2 (en) 2005-08-04
JP2003519656A (ja) 2003-06-24
WO2001051050A1 (en) 2001-07-19
IL150696A0 (en) 2003-02-12
JP5944943B2 (ja) 2016-07-05
JP2014133775A (ja) 2014-07-24
EP1430895A1 (en) 2004-06-23
US20050042304A1 (en) 2005-02-24
US20090022796A1 (en) 2009-01-22
IL150696A (en) 2009-05-04
NO20023313L (no) 2002-08-30
EP1246622B1 (en) 2006-09-27
AU2005229686A1 (en) 2005-12-01
JP2012136531A (ja) 2012-07-19
NO20023313D0 (no) 2002-07-09
NZ520121A (en) 2005-04-29
CA2396159C (en) 2007-11-13
JP4991432B2 (ja) 2012-08-01
US20040058018A1 (en) 2004-03-25
US20030144306A1 (en) 2003-07-31
DE60123381T2 (de) 2007-08-09
JP2007277271A (ja) 2007-10-25
RU2002121623A (ru) 2004-03-20
EP2305259A1 (en) 2011-04-06
US20030118669A1 (en) 2003-06-26
DK1246622T3 (da) 2007-01-29
EP1246622A1 (en) 2002-10-09
US20030215527A1 (en) 2003-11-20
US6489346B1 (en) 2002-12-03
AU3276701A (en) 2001-07-24
ZA200205512B (en) 2004-02-10
PL201906B1 (pl) 2009-05-29
US7399772B2 (en) 2008-07-15
PL357144A1 (en) 2004-07-12
MXPA02006780A (es) 2003-10-06
EP1246622A4 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
DK1117383T3 (da) Doseringsformer omfattende terapeutisk formulering
HRP20030951B1 (hr) Formulacije jednodnevnih doza oksikodona
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
EE04451B1 (et) Pulberinhalaatori kapsel farmatseutiliste preparaatide mahutamiseks
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO970036D0 (no) Nytt oralt, farmasöytisk preparat inneholdende magnesiumsalt av omeprazol
SE9700885D0 (sv) New pharmaceutical formulation
NO20026123D0 (no) Farmasöytiske sammensetninger
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
EA199900102A1 (ru) Таблетка малеата тримебутина, покрытая оболочкой
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
EA200300110A1 (ru) Композиция элетриптана в виде частиц
FR2677021B1 (fr) Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
HRP20010764B1 (en) Prucalopride oral solution
NO975680D0 (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
BR9708280A (pt) Compostos de inclusão de diclofenaco/gama-cd
GEP20043377B (en) Pharmaceutical Complex
HRP20040303B1 (en) Use of specific dose of fondaparinux sodium for the treatment of acs
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them